Evidence map›Paper›PMID 27647871›Full record

ArticleInfection and immunity2016

Influenza A Virus Infection Predisposes Hosts to Secondary Infection with Different Streptococcus pneumoniae Serotypes with Similar Outcome but Serotype-Specific Manifestation.

Niharika Sharma-Chawla, Vicky Sender, Olivia Kershaw, Achim D Gruber, Julia Volckmar, Birgitta Henriques-Normark, Sabine Stegemann-Koniszewski, Dunja Bruder

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in cellular and infection microbiology · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Non-capsular based immunization approaches to preventFrontiers in cellular and infection microbiology · 2022
    Review
  14. Secondary infection withFEMS microbes · 2022
    Article
  15. Article
  16. Article
  17. Altered Signal Transduction in the Immune Response to Influenza Virus andInternational journal of molecular sciences · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Niharika Sharma-ChawlaImmune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Vicky SenderDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Olivia KershawDepartment of Veterinary Medicine, Institute of Veterinary Pathology, Free University Berlin, Berlin, Germany.
Achim D GruberDepartment of Veterinary Medicine, Institute of Veterinary Pathology, Free University Berlin, Berlin, Germany.
Julia VolckmarImmune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Birgitta Henriques-NormarkDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Sabine Stegemann-KoniszewskiImmune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany Sabine.Stegemann-Koniszewski@helmholtz-hzi.de Dunja.Bruder@med.ovgu.de.
Dunja BruderImmune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany Sabine.Stegemann-Koniszewski@helmholtz-hzi.de Dunja.Bruder@med.ovgu.de.
Helmholtz Centre for Infection Research · DEFreie Universität Berlin · DEKarolinska Institutet · SEOtto-von-Guericke University Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza A virus (IAV) and Streptococcus pneumoniae are major causes of respiratory tract infections, particularly during coinfection. The synergism between these two pathogens is characterized by a complex network of dysregulated immune responses, some of which last until recovery following IAV infection. Despite the high serotype diversity of S. pneumoniae and the serotype replacement observed since the introduction of conjugate vaccines, little is known about pneumococcal strain dependency in the enhanced susceptibility to severe secondary S. pneumoniae infection following IAV infection. Thus, we studied how preinfection with IAV alters host susceptibility to different S. pneumoniae strains with various degrees of invasiveness using a highly invasive serotype 4 strain, an invasive serotype 7F strain, and a carrier serotype 19F strain. A murine model of pneumococcal coinfection during the acute phase of IAV infection showed a significantly increased degree of pneumonia and mortality for all tested pneumococcal strains at otherwise sublethal doses. The incidence and kinetics of systemic dissemination, however, remained bacterial strain dependent. Furthermore, we observed strain-specific alterations in the pulmonary levels of alveolar macrophages, neutrophils, and inflammatory mediators ultimately affecting immunopathology. During the recovery phase following IAV infection, bacterial growth in the lungs and systemic dissemination were enhanced in a strain-dependent manner. Altogether, this study shows that acute IAV infection predisposes the host to lethal S. pneumoniae infection irrespective of the pneumococcal serotype, while the long-lasting synergism between IAV and S. pneumoniae is bacterial strain dependent. These results hold implications for developing tailored therapeutic treatment regimens for dual infections during future IAV outbreaks.

Indexed as

Influenza A virusSerogroupAnimalsCoinfectionFemaleImmunity, InnateMiceOrthomyxoviridae InfectionsPneumococcal InfectionsStreptococcus pneumoniaeViral Load

Identifiers

PMID27647871
PMCPMC5116722
OpenAlexW2523421524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.